Wisconsin is currently home to 1287 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
03/10/2025
Locations: Langlade Hospital and Cancer Center, Antigo, Wisconsin
Conditions: Breast Cancer
Register for Updates
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245
Recruiting
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/10/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Venous Thromboembolism
Register for Updates
Platform Clinical Study for Conquering Scleroderma
NCT06195072
Recruiting
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Register for Updates
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379
Recruiting
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Research Site, Madison, Wisconsin
Conditions: Breast Cancer
Register for Updates
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Wisconsin (Carbone Cancer Center), Madison, Wisconsin
Conditions: Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer)
Register for Updates
LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF
NCT05983250
Recruiting
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/07/2025
Locations: Tenax Investigational Site, Madison, Wisconsin
Conditions: Pulmonary Hypertension
Register for Updates
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
NCT05822583
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: William S. Middleton Memorial Veterans Hospital (074-030), Madison, Wisconsin
Conditions: COVID-19
Register for Updates
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
NCT05685602
Recruiting
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 As Monotherapy and Combination Therapy in Subjects with BRAF V600 Mutant Solid Tumors
NCT05668585
Recruiting
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Solid Tumors, Melanoma, NSCLC, CRC, ATC
Register for Updates
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211
Recruiting
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/07/2025
Locations: Research Site, Madison, Wisconsin
Conditions: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Register for Updates
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
NCT05109975
Recruiting
This study has two parts: Part 1 and Part 2. The purpose of this study in Part 1, Dose Escalation Part is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of Debio 0123 as monotherapy with repeated dosing in adults with advanced solid tumors that recurred or progressed after prior therapy and/or for whom no standard therapy of proven benefit is available. The purpose in Part 2, Expansion Part of this study, is to characterize the safety and tolerability o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Advanced Solid Tumors
Register for Updates
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722
Recruiting
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Froedtert Hospital / Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Register for Updates